Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
48.09
-0.34 (-0.70%)
Jan 23, 2025, 3:39 PM EST - Market open
Soleno Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
2.07B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.95B |
SLNO News
- 5 weeks ago - Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC - GlobeNewsWire
- 2 months ago - Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 - GlobeNewsWire
- 3 months ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
- 3 months ago - SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval - GuruFocus
- 4 months ago - Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc - GuruFocus
- 4 months ago - Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire